Novo Nordisk Stock Plummets After Wegovy Sales Forecast Cut

Novo Nordisk Stock Plummets After Wegovy Sales Forecast Cut

Danish pharmaceutical giant Novo Nordisk experienced a significant stock drop on Tuesday, with shares plummeting 15% in London following a revised financial outlook.

The company lowered its full-year sales and profit guidance, attributing the adjustment to weaker-than-expected growth of its obesity drug, Wegovy, particularly in the U.S. market.

The announcement triggered immediate market reaction, prompting investors to reassess the stock's potential.

The situation is still developing, and further updates are anticipated.